In a world built on antibiotics that can’t finish a fight they started, Maxwell Biosciences isn’t just entering the ring, they’re walking in like they already know the belt’s theirs. On August 7, 2025, the Austin-based health tech heavyweight announced a fresh $20 million financing round, a strong follow-up to their $10.8 million seed back in 2022. No flash, no fluff, just a company with real teeth and a platform that might be the immune system’s best sequel since evolution.
Founded in 2016 by Joshua “Scotch” McClure, U.S. Air Force vet, multi-patent inventor, and CEO who moves like he’s already seen the next five chess moves, Maxwell is building Claromers: immune-inspired small molecules that don’t ask pathogens nicely to leave. They mimic LL-37, the body’s frontline peptide, with one mission: destroy the bad guys, leave the good guys alone, and skip the microbiome collateral damage. This isn’t a new class of antibiotics. It’s a full genre shift.
Co-founded with Dr. Annelise Barron, and backed early by DARPA, DOE, and NIH, this isn’t your garden-variety startup story. Claromers aren’t just effective against bacteria and viruses, they’ve shown preclinical firepower against pan coronavirus strains, pan influenza variants, Ebola, drug-resistant fungi, and biofilms that laugh in the face of traditional medicine. Stanford, NYU, Texas A&M, and Baylor College of Medicine have all tested the tech. The results don’t whisper, they scream.
Let’s talk usage: this latest round pushes Maxwell into FDA trials in 2026, with MXB-22,510 leading the charge for chronic rhinosinusitis. But pharma is just one lane. Think cosmetics. Cleaning products. Medical device coatings. The kind of anti-infective tech that doesn’t just treat disease, it redesigns the operating environment. No cold chain. No pathogen adaptation. No problem.
The team? Edward M. Rudnic, Ph.D. runs ops and R&D like a man who’s authored 56 patents for sport. Dr. Tony Verco brings decades of clinical expertise, while Jon McClure steers AI as CTO of the division launched this year. Their board reads like a who’s-who of pharma leadership and biodefense, from Kate McKinley to MG (Ret.) Barbara Holcomb.
Investors like DecentraNet, Star Lake Bioventures, Longevitytech.fund, and Harvard Business School Angels doubled down, and it’s no mystery why. Maxwell isn’t selling hype. They’re selling a platform that’s clinically validated, AI-powered, and globally scalable. Call it the Maxwell Effect: precision biology, military-grade partnerships, and tech that doesn’t blink.
